Liraglutide
Also known as: Victoza, Saxenda
Liraglutide is a GLP-1 receptor agonist approved in Australia as a prescription medicine for type 2 diabetes and, under separate branding, weight management. Grey-market versions are not approved.
- Category
- Metabolic / GLP-1
- Reported half-life
- Reported ~13 hours, supporting once-daily dosing of the approved product
- Common forms
- Pre-filled injection pen (approved prescription product), Grey-market vials (not approved)
- Research status
- Prescription-only medicine in Australia (approved by the TGA for specified indications). Grey-market versions are not approved and sit outside the regulated supply chain.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Demonstrated in clinical trials to lower blood glucose in type 2 diabetes
- Shown in trials to support weight reduction alongside diet and lifestyle
- Reported to reduce appetite and slow gastric emptying
How it is reported to work
Liraglutide is reported to mimic GLP-1, a gut hormone that stimulates insulin release when blood sugar is high, suppresses glucagon and slows gastric emptying. These actions are reported to reduce appetite and improve glucose control. Unlike many peptides on this site, these mechanisms are supported by large human clinical trials.
Background
Liraglutide is a GLP-1 receptor agonist and one of the earlier medicines in this class. It is sold under brand names including Victoza (type 2 diabetes) and Saxenda (weight management). Like semaglutide, it is an approved prescription medicine in Australia with a substantial clinical-trial evidence base. This page is educational and is not medical advice; it does not recommend use.
What the research shows
Liraglutide has been studied in large randomised trials, including the LEAD programme (diabetes) and the SCALE programme (weight). These trials reported meaningful effects on glucose control and body weight, though results vary between individuals and side effects require professional oversight.
| Programme | Focus | Outcome reported |
|---|---|---|
| LEAD | Type 2 diabetes | Improved glucose control |
| SCALE | Weight management | Reduced body weight |
What people use it for (regulated indications)
In Australia, liraglutide is prescribed for type 2 diabetes and, under separate branding, weight management in eligible patients, as determined by a healthcare professional.
Things to be aware of
There is an important distinction between the TGA-approved product and grey-market “liraglutide” sold outside the regulated supply chain, whose purity, identity and content cannot be assured, which is why independent testing is discussed in this community. Reported side effects include nausea and other gastrointestinal effects, with rarer serious reactions possible, and individual responses vary. Because liraglutide is prescription-only, it should only be used under medical supervision by a qualified healthcare professional who can assess suitability. This article explains what liraglutide is and what the evidence shows; it is educational, does not recommend any dose, and does not direct anyone to obtain or use it.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Demonstrated in trials to lower blood glucose in type 2 diabetes
- Shown in trials to support weight reduction alongside diet and lifestyle
- Reported to reduce appetite and slow gastric emptying
- Reported cardiovascular benefit in specific approved populations
Common side effects
- Reported nausea, especially when starting or increasing the dose
- Reported vomiting, diarrhoea or constipation
- Reported reduced appetite and indigestion
- Reported injection-site reactions and headache
Rare / serious side effects
- Reported pancreatitis in a small number of cases
- Reported gallbladder problems, including gallstones, with rapid weight loss
- Reported hypoglycaemia when combined with insulin or sulfonylureas
- Reported serious allergic reactions in rare instances
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Liraglutide. Listed so you can make an informed decision, not to suggest any use is safe.
- Using unverified grey-market vials is reported to carry dosing-error, contamination and potency-uncertainty risks because they sit outside the regulated supply chain.
- Self-dosing without medical supervision is reported to risk severe dehydration and electrolyte loss when persistent nausea, vomiting and diarrhoea go unmanaged.
- Escalating the dose too quickly is reported to provoke intense GI effects and, with combined glucose-lowering drugs, dangerous hypoglycaemia.
- Overuse for rapid weight loss is reported to strain the gallbladder and pancreas and contribute to muscle loss from inadequate intake.
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Appetite effects are reported within days of starting, while meaningful weight and glucose changes are reported to develop over months.
First effects
Reported appetite suppression within the first days
Noticeable change
Reported early appetite and glucose changes
Clear results
Reported meaningful weight and glucose changes over months
Peak effect
Reported fuller weight-management effect with continued use
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Liraglutide. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous injection via pre-filled pen |
|---|---|
| Typical reported dose | Approved labelling reports starting at 0.6 mg per day and titrating to 1.2–3.0 mg per day (Saxenda reaches 3.0 mg per day) |
| Frequency | Reported as once daily |
| Cycle length | Used as an ongoing daily therapy under the approved product labelling rather than in cycles |
Reported reconstitution (mg → units)
The approved pen is pre-dosed and not reconstituted. Illustration only for a compounded vial: an 18 mg vial + 3 mL bacteriostatic water = 6 mg/mL. A 1.2 mg dose is about 0.2 mL = 20 units on a U-100 insulin syringe.
Work out the units for your vial → CalculatorAs an approved prescription product, liraglutide is reported as a once-daily injection with gradual dose escalation under medical supervision; framed as reported information, not advice. Grey-market versions are not TGA-approved.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Reported as a comparator GLP-1 agonist with less frequent dosing
Reported as a comparator weekly GLP-1 agonist
Reported as a comparator incretin agonist in metabolic discussion
Safety notes
As a prescription-only medicine, liraglutide should only be used under the supervision of a qualified healthcare professional who can assess suitability and monitor side effects such as nausea and gastrointestinal upset, plus rarer serious reactions. Grey-market versions are not TGA-approved and their quality cannot be assured. Do not use any version without medical guidance.